-
CHARACTERIZING REAL-WORLD DISEASE BURDENS IN CARDIAC AMYLOIDOSIS: A DESCRIPTIVE STUDY ON SOCIAL, ECONOMIC, AND ACCESS-RELATED IMPACTS ON PATIENTS IN GERMANY AND SPAIN
Feb 25, 2026, 14:42 PM -
EFFECTIVENESS OF COMMUNITY-BASED AND HOME-BASED HEALTH INTERVENTIONS FOR HEALTHY AGING IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF INTEGRATING BREAST CANCER SCREENING INTO AN EXISTING CERVICAL CANCER SCREENING PROGRAM IN CAMEROON
Feb 25, 2026, 14:42 PM -
ECONOMIC VALUE OF RSV MATERNAL VACCINATION TO PREVENT INFANT DISEASE IN ECUADOR
Feb 25, 2026, 14:42 PM -
REAL-WORLD INSIGHTS INTO OBESITY PATHWAYS, PRESCRIBING, PATIENT COMPLEXITY, AND CARE GAPS THROUGH PRIMARY CARE DATABASES
Feb 25, 2026, 14:42 PM -
REAL-WORLD TREATMENT PATTERNS, OUTCOMES, HCRU AND COSTS ASSOCIATED WITH PREVIOUSLY-TREATED EXTENSIVE-STAGE SCLC IN THE US FOLLOWING THE APPROVAL OF NEWER TREATMENT OPTIONS
Feb 25, 2026, 14:42 PM -
PATIENT ATTITUDES TO SHARED DECISION-MAKING AND INNOVATIONS IN MUSCLE INVASIVE BLADDER CANCER: A MULTI-COUNTRY FOCUS GROUP
Feb 25, 2026, 14:42 PM -
GLOBAL REGULATORY ASYMMETRIES AND THE STRUCTURAL DRUG LAG: TIME TO MARKET AUTHORIZATION IN CÔTE D’IVOIRE
Feb 25, 2026, 14:42 PM -
REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:42 PM -
CROSS-VALIDATION OF AN EARLY COST-EFFECTIVENESS MODEL FOR SPECTRIS™ THERAPY USING THE ALZHEIMER’S DISEASE OPEN-SOURCE IPECAD MODEL FRAMEWORK
Feb 25, 2026, 14:42 PM -
ASSESSING DISTRIBUTION OF SOCIAL AND PRIVATE VALUE CREATION BY DRUGS REGULATING PROGRAMMED CELL DEATH-1IN CANCER TREATMENT...
Feb 25, 2026, 14:42 PM -
ACCOUNTING FOR RISK-AVERSION IN HEALTH TECHNOLOGY ASSESSMENT: UTILITY ESTIMATION ACROSS MULTIPLE HEALTH INDEXES IN NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:42 PM -
EVALUATING INITIAL MEDICATION ADHERENCE THRESHOLDS AS PREDICTORS OF CONTINUATION ADHERENCE AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A CLAIMS-BASED ANALYSIS
Feb 25, 2026, 14:42 PM -
REAL-WORLD PERIOPERATIVE IMMUNOTHERAPY AND CELLULAR THERAPY IN OLDER ADULTS WITH SOLID TUMORS: A 2021-2025 MEDICARE-EMR LINKED ANALYSIS
Feb 25, 2026, 14:42 PM -
ALIGNMENT OF PATIENT-REPORTED OUTCOME IMPROVEMENTS WITH ICER COST-EFFECTIVENESS AND VALUE-BASED PRICE RECOMMENDATIONS IN RHEUMATOID ARTHRITIS
Feb 25, 2026, 14:42 PM -
REAL-WORLD HEALTHCARE UTILIZATION AND CLINICAL CHARACTERISTICS ACROSS DIABETES COMPLICATIONS SEVERITY IN MEDICARE ADVANTAGE INSURED ADULTS WITH TYPE 2 DIABETES
Feb 25, 2026, 14:42 PM -
EVALUATING PATIENT PREFERENCES FOR COPD MAINTENANCE TREATMENT DELIVERY DEVICES: A DISCRETE CHOICE EXPERIMENT
Feb 25, 2026, 14:42 PM -
ECOA METATEXT DEVELOPMENT: AN ESSENTIAL STEP IN MAINTAINING UX/UI ACROSS ALL LANGUAGES IN ECOA SOLUTIONS
Feb 25, 2026, 14:42 PM -
DEPRESCRIBING PREVENTIVE MEDICATIONS IN OLDER ADULTS WITH ADVANCED FRAILTY, DEMENTIA, OR LIMITED LIFE EXPECTANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:42 PM -
WHO IS MOST AT RISK OF UNRECOGNIZED DIABETES? A STUDY TO INFORM PHARMACIST ACTION
Feb 25, 2026, 14:42 PM
